Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Epilepsia. 2021 Mar;62(3):709-719. doi: 10.1111/epi.16827. Epub 2021 Feb 5.
Prenatal exposure to the antiepileptic drug (AED) valproic acid (VPA) is associated with an increased risk of impaired postnatal neurodevelopment, including autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We aimed to evaluate the influence of sex and drug dosage on the association between prenatal VPA exposure and postnatal behavioral outcomes.
The Australian Pregnancy Register of AEDs was interrogated to identify children aged 4-11 years prenatally exposed to AEDs. Parents reported on their child's behavior using the Autism Spectrum Quotient-Children's Version and the National Institute for Children's Health Quality Vanderbilt Assessment Scale for ADHD. General linear mixed-effects models were used to investigate the relationship between clinicodemographic variables and psychometric scores.
A total of 121 children were studied: 54 prenatally exposed to VPA (28 males, 26 females; mean dose ± SD: 644 ± 310 mg/day) and 67 exposed to other AEDs. There was a main effect of sex showing higher ASD scores in males compared to females (p = .006). An interaction between sex and VPA exposure revealed that males had higher ASD symptoms among children exposed to AEDs other than VPA (p = .01); however, this typical sex dynamic was not evident in VPA-exposed children. There was no evidence of any dose-response relationship between VPA exposure and ASD symptoms. Males had higher ADHD scores compared to females, but there was no evidence for a link between ADHD symptoms and VPA exposure.
Prenatal VPA exposure seems to negate the usual male sex-related predominance in the incidence of ASD. These initial findings deepen the concept of VPA as a "behavioral teratogen" by indicating that its effect might be influenced by sex, with females appearing particularly sensitive to the effects of VPA. No association between VPA doses and adverse postnatal behavioral outcomes was detected, possibly related to the low VPA doses used in this study.
产前暴露于抗癫痫药物(AED)丙戊酸(VPA)会增加出生后神经发育受损的风险,包括自闭症谱系障碍(ASD)和注意缺陷多动障碍(ADHD)。我们旨在评估性别和药物剂量对产前 VPA 暴露与出生后行为结果之间关联的影响。
澳大利亚 AED 妊娠登记处被查询以确定在怀孕期间接触过 AED 的 4-11 岁儿童。父母使用自闭症谱系商数儿童版和国家儿童健康质量范德比尔特评估量表 ADHD 报告他们孩子的行为。使用广义线性混合效应模型研究临床人口统计学变量与心理测量评分之间的关系。
共研究了 121 名儿童:54 名产前暴露于 VPA(28 名男性,26 名女性;平均剂量±SD:644±310mg/天)和 67 名暴露于其他 AED。性别存在主要影响,男性的 ASD 评分高于女性(p=0.006)。性别与 VPA 暴露之间的相互作用表明,暴露于除 VPA 以外的 AED 的儿童中,男性的 ASD 症状更高(p=0.01);然而,这种典型的性别动态在 VPA 暴露的儿童中并不明显。VPA 暴露与 ASD 症状之间没有证据表明存在剂量反应关系。男性的 ADHD 评分高于女性,但没有证据表明 ADHD 症状与 VPA 暴露有关。
产前 VPA 暴露似乎否定了 ASD 发病率中通常的男性性别优势。这些初步发现深化了 VPA 作为“行为致畸剂”的概念,表明其影响可能受到性别的影响,女性对 VPA 的影响似乎特别敏感。未发现 VPA 剂量与不良出生后行为结果之间存在关联,这可能与本研究中使用的低 VPA 剂量有关。